Fairooz F. Kabbinavar
About Fairooz F. Kabbinavar
Fairooz F. Kabbinavar is a distinguished oncologist and the Chief Medical Officer with extensive experience in clinical development and research, particularly in immuno-oncology and genitourinary cancers.
Chief Medical Officer
Fairooz F. Kabbinavar currently holds the title of Chief Medical Officer. With a focus on clinical oncology, Kabbinavar brings extensive experience in medical direction and research to his role. This professional position emphasizes his leadership in overseeing medical strategies, clinical operations, and development within his organization.
Clinical Development Leadership
Fairooz Kabbinavar has a notable career leading clinical development programs. As Senior VP at Tocagen, Inc., PUMA Biotechnology, and Global Head of R&D at HUYABIO International, he has directed multiple initiatives advancing cancer treatment research. His expertise extends to his role at Genentech, where he served as Principal Medical Director in the atezolizumab (TECENTRIQ) immuno-oncology program.
Medical Training and Fellowship
Fairooz Kabbinavar's medical training started at Nagpur University in India, where he obtained his B.Sc., M.B.B.S., and M.D. degrees. He furthered his education in the United States, completing his internship and residency at Harvard University’s Beth Israel Deaconess Medical Center. Kabbinavar also completed a postdoctoral research fellowship and a clinical hematology-oncology fellowship at UCLA.
Academic and Clinical Roles at UCLA
Kabbinavar's tenure at UCLA is marked by significant contributions since joining in 1994. Starting as a Clinical Instructor, he achieved the rank of Professor of Medicine by 2008. He has held the prestigious Henry Alvin and Carrie L. Meinhardt Endowed Chair in Oncology and served as Medical Director of the Institute of Urologic Oncology. His roles also included the Director of Medical Oncology Programs in Genitourinary and Lung & Head & Neck Cancers at UCLA.
Research and Publications
Fairooz Kabbinavar has been an active researcher, participating in over 100 clinical trials as a principal or sub-investigator. He has published over 100 peer-reviewed research papers and authored more than 150 abstracts. His work includes contributions to renowned journals such as NEJM, JCO, Clinical Cancer Research, and EJC. He is also responsible for two book chapters, highlighting his influential presence in oncology research.